Veteran healthcare executive and investor with operational and board experience across medical device and services companies. Kent D. Aloia has led strategic growth, M&A and commercialization initiatives and often partners with PE firms to scale specialty healthcare businesses. Known for combining surgical practice insight with corporate governance, he has served as CEO and board director roles and advised growth-stage management teams on product strategy and market development. Relevant to investors seeking experienced operating partners in healthcare roll-ups, digital health and device commercialization.
Veteran healthcare executive and investor with operational and board experience across medical device and services companies. Kent D. Aloia has led strategic growth, M&A and commercialization initiatives and often partners with PE firms to scale specialty healthcare businesses. Known for combining surgical practice insight with corporate governance, he has served as CEO and board director roles and advised growth-stage management teams on product strategy and market development. Relevant to investors seeking experienced operating partners in healthcare roll-ups, digital health and device commercialization.
Seasoned healthcare operating partner who prioritizes equity investments that leverage deep medical-device and specialty services expertise to accelerate commercialization and roll-up strategies. Prefers control or structured minority stakes where active governance, clinical insights and go-to-market operational resources can derisk regulatory and reimbursement pathways. Focuses on multi-year value creation through M&A-driven scale, product-market fit, and commercialization execution, applying disciplined capital allocation, milestone-based funding and outcome-oriented KPIs to balance growth and clinical/risk governance.
Seasoned healthcare operating partner who prioritizes equity investments that leverage deep medical-device and specialty services expertise to accelerate commercialization and roll-up strategies. Prefers control or structured minority stakes where active governance, clinical insights and go-to-market operational resources can derisk regulatory and reimbursement pathways. Focuses on multi-year value creation through M&A-driven scale, product-market fit, and commercialization execution, applying disciplined capital allocation, milestone-based funding and outcome-oriented KPIs to balance growth and clinical/risk governance.
| Trades 669 | Longs Won 493/669 73% | Profit Factor 19.75 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $568,113.46 |
| Average Win $106,304.08 | Best Trade (Aug 14) $13.34M | Sharpe Ratio -14.82 |
| Average Loss -$15,075.21 | Worst Trade (Aug 02) -$363,366.77 | Z-Score 15.08 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 2d | Expectancy $74,371.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 13,889 | 12,500 | 11,111 | 9,722 | 8,333 | 6,944 | 5,556 | 4,167 | 2,778 | 1,389 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 7,616 | $1.66M | $2.35M | - | $694,695.32 | 41.9% | -7.354% |
ABBV AbbVie Inc. | 1,038 | $240,158.76 | $260,475.72 | - | $20,316.96 | 8.46% | -2.513% |
AGG iShares Core U.S. Aggregate Bond ETF | 9,255 | $918,298.75 | $901,159.35 | - | -$17,139.4 | -1.87% | -0.256% |
AMAT Applied Materials, Inc. | 371 | $267,988 | $188,345.57 | - | -$79,642.43 | -29.72% | +1.176% |
AMD Advanced Micro Devices, Inc. | 675 | $392,114 | $321,401.24 | - | -$70,712.76 | -18.03% | -1.904% |
AMGN Amgen Inc. | 601 | $197,042.46 | $231,481.16 | - | $34,438.7 | 17.48% | -0.64% |
AMZN Amazon.com Inc | 4,962 | $1M | $1.35M | - | $343,913.98 | 34.27% | +15.321% |
AVGO Broadcom Inc. | 1,965 | $505,423.56 | $764,935.2 | - | $259,511.64 | 51.35% | +0.371% |
AXP American Express Company | 818 | $262,962.26 | $275,052.5 | - | $12,090.24 | 4.6% | -0.376% |
BIV Vanguard Intermediate-Term Bond ETF (likely mapping for ticker 0V1L) | 365,539 | $28.06M | $27.61M | - | -$449,788.1 | -1.6% | -0.198% |
BND Vanguard Total Bond Market Index Fund | 3,069 | $225,969.59 | $221,673.87 | - | -$4,295.72 | -1.9% | -0.262% |
BRK-B Berkshire Hathaway Inc. | 892 | $466,971.87 | $456,293.68 | - | -$10,678.19 | -2.29% | +0.365% |
BSV Vanguard Short-Term Bond ETF | 5,159 | $406,087.02 | $400,235.22 | - | -$5,851.8 | -1.44% | -0.077% |
CAT Caterpillar Inc. | 301 | $218,395.37 | $245,257.81 | - | $26,862.44 | 12.3% | +0.701% |
CEG Constellation Energy Corporation | 856 | $276,770.34 | $224,914 | - | -$51,856.34 | -18.74% | -0.307% |
CSCO Cisco Systems, Inc. | 1,804 | $211,891 | $209,245.96 | - | -$2,645.04 | -1.25% | +2.14% |
DKS Dick's Sporting Goods, Inc. | 1,552 | $234,030.73 | $304,052.32 | - | $70,021.59 | 29.92% | -2.001% |
EEM iShares MSCI Emerging Markets ETF | 79,901 | $3.35M | $5.12M | - | $1.77M | 52.95% | +0.786% |
EFA iShares MSCI EAFE ETF | 109,261 | $8.42M | $11.54M | - | $3.12M | 37.05% | -0.621% |
EMXC iShares MSCI Emerging Markets ex China ETF | 2,311 | $236,444 | $212,889.32 | - | -$23,554.68 | -9.96% | +1.031% |